Which coagulation protein exclusively functions to create covalent bonds between the fibrin monomers formed during the coagulation (blood clotting) process to form a stable fibrin clot?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Factor XIII is the Coagulation Protein That Creates Covalent Bonds Between Fibrin Monomers

Factor XIII is the coagulation protein that exclusively functions to create covalent bonds between fibrin monomers formed during the coagulation process to form a stable fibrin clot. 1

Mechanism of Factor XIII in Fibrin Stabilization

Factor XIII plays a critical role in the final stages of blood coagulation through the following mechanism:

  • Factor XIII circulates in blood as a heterotetramer with two catalytic A subunits and two carrier B subunits (FXIII-A₂B₂) 1
  • During coagulation, thrombin cleaves an activation peptide from each FXIII-A subunit
  • In the presence of calcium, the B subunits dissociate, allowing the A subunits to assume an active configuration (FXIIIa) 1
  • FXIIIa functions as a transglutaminase that catalyzes the formation of covalent bonds between fibrin monomers 1, 2
  • These covalent bonds are formed specifically between the α and α chains, resulting in γ-γ dimers and α polymers 1

Importance of Factor XIII in Clot Stability

The covalent cross-linking of fibrin by Factor XIII is essential for:

  • Converting soluble fibrin monomers into a stable fibrin clot 2
  • Preventing premature degradation of fibrin by the fibrinolytic system 3
  • Reinforcing the fibrin structure to withstand mechanical stress 1
  • Enabling the body to stop potential bleeding episodes effectively 3

Clinical Significance of Factor XIII

The critical role of Factor XIII in clot stability is evidenced by the consequences of its deficiency:

  • In Factor XIII deficiency, although initial clot formation occurs, the clot is rapidly degraded by the fibrinolytic system 3
  • This results in delayed bleeding, which can be severe and life-threatening 3, 4
  • Factor XIII deficiency can be congenital (rare, 1 per million) or acquired (more common) 2

Distinguishing Factor XIII from Other Coagulation Factors

It's important to understand how Factor XIII differs from the other options presented:

  • Factor XII (Option A): Initiates the intrinsic pathway of coagulation but does not create covalent bonds between fibrin monomers 5
  • Factor II (Option C): Also known as prothrombin, converts to thrombin which cleaves fibrinogen to form fibrin monomers but does not create covalent bonds between them 5
  • Factor IX (Option D): Functions in the intrinsic pathway of coagulation, activating Factor X, but is not involved in creating covalent bonds between fibrin monomers 5

The unique role of Factor XIII as the "fibrin-stabilizing factor" that creates covalent bonds between fibrin monomers makes it the correct answer to this question.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Factor XIII and surgical bleeding.

Minerva anestesiologica, 2022

Research

Current understanding in diagnosis and management of factor XIII deficiency.

Iranian journal of pediatric hematology and oncology, 2013

Research

Acquired FXIII inhibitors: a systematic review.

Journal of thrombosis and thrombolysis, 2013

Guideline

Protein S Deficiency and Thrombosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.